Arvinas Inc (ARVN)
24.74
+0.38
(+1.56%)
USD |
NASDAQ |
Sep 27, 16:00
24.73
-0.01
(-0.04%)
After-Hours: 20:00
Arvinas SG&A Expense (Annual): 100.30M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 100.30M |
| December 31, 2022 | 79.60M |
| December 31, 2021 | 61.60M |
| December 31, 2020 | 38.30M |
| Date | Value |
|---|---|
| December 31, 2019 | 27.30M |
| December 31, 2018 | 12.93M |
| December 31, 2017 | 3.546M |
| December 31, 2016 | 3.196M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
27.30M
Minimum
2019
100.30M
Maximum
2023
61.42M
Average
61.60M
Median
2021
SG&A Expense (Annual) Benchmarks
| EyePoint Pharmaceuticals Inc | 51.79M |
| HOOKIPA Pharma Inc | 18.63M |
| NovaBay Pharmaceuticals Inc | 12.83M |
| Palatin Technologies Inc | 15.29M |
| iBio Inc | 11.67M |